Literature DB >> 9316538

Cardiac troponin I levels are normal or minimally elevated after transthoracic cardioversion.

J J Allan1, R D Feld, A A Russell, J H Ladenson, M A Rogers, R E Kerber, A S Jaffe.   

Abstract

OBJECTIVES: The present study was designed to assess the impact of direct current shocks on cardiac troponin I (cTnI), which has greater sensitivity and specificity than creatine kinase (CK) for the diagnosis of myocardial injury.
BACKGROUND: Transthoracic direct current shocks can cause myocardial injury. They also cause elevations of total CK and CK-MB fraction (CK-MB).
METHODS: We obtained measurements of cTnI total CK and CK-MB before and after elective cardioversions in 38 patients. Blood samples were drawn before and 8, 16, 24 and 48 h after cardioversion. Shock energy, current, impedance and number of shocks delivered were tabulated.
RESULTS: Patients received a mean (+/-SD) of 2.1 +/- 1.2 shocks with a median cumulative energy of 300 J (range 50 to 1,580). Three patients had minimal elevations (1.5, 1.2 and 0.8 ng/ml, normal < or = 0.6 ng/ml) of cTnI. Two of these patients had impaired left ventricular contractility by echocardiography. Thirty-five of the 38 patients had no elevations of cTnI. Sixty-two percent of patients had an increase in CK after cardioversion, but CK-MB was elevated to an abnormal level of 12.7 ng/ml (normal < 6.7) in only one patient after cardioversion.
CONCLUSIONS: Cardiac troponin I levels are either normal or minimally elevated after elective direct current cardioversion, suggesting that subtle myocardial injury can be caused by direct current transthoracic shocks. However, substantial elevations of cTnI after cardioversion suggest the presence of myocardial injury from causes unrelated to the direct current shocks administered for cardioversion.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9316538     DOI: 10.1016/s0735-1097(97)00260-x

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  8 in total

Review 1.  Troponin: the biomarker of choice for the detection of cardiac injury.

Authors:  Luciano Babuin; Allan S Jaffe
Journal:  CMAJ       Date:  2005-11-08       Impact factor: 8.262

2.  Cardioversion of Atrial Fibrillation and Flutter: Comparative Study of Pulsed vs. Low Energy Biphasic Truncated Exponential Waveforms.

Authors:  Delphine Lavignasse; Elina Trendafilova; Elena Dimitrova; Vessela Krasteva
Journal:  J Atr Fibrillation       Date:  2019-10-31

Review 3.  MicroRNAs as biomarkers for myocardial infarction.

Authors:  Kanita Salic; Leon J De Windt
Journal:  Curr Atheroscler Rep       Date:  2012-06       Impact factor: 5.113

Review 4.  Cardiac Troponins in Dogs and Cats.

Authors:  R Langhorn; J L Willesen
Journal:  J Vet Intern Med       Date:  2015-12-17       Impact factor: 3.333

5.  Troponin Marker for Acute Coronary Occlusion and Patient Outcome Following Cardiac Arrest.

Authors:  David A Pearson; Catherine M Wares; Katherine A Mayer; Michael S Runyon; Jonathan R Studnek; Shana L Ward; Kathi M Kraft; Alan C Heffner
Journal:  West J Emerg Med       Date:  2015-12-08

6.  Cardioversion Efficacy Using Pulsed Biphasic or Biphasic Truncated Exponential Waveforms: A Randomized Clinical Trial.

Authors:  Anders S Schmidt; Kasper G Lauridsen; Kasper Adelborg; Peter Torp; Leif F Bach; Simon M Jepsen; Nete Hornung; Charles D Deakin; Hans Rickers; Bo Løfgren
Journal:  J Am Heart Assoc       Date:  2017-03-08       Impact factor: 5.501

7.  Evidence for Acute Myocardial and Skeletal Muscle Injury after Serial Transthoracic Shocks in Healthy Swine.

Authors:  Dominik P Guensch; Janelle Yu; Gobinath Nadeshalingam; Kady Fischer; Jane Shearer; Matthias G Friedrich
Journal:  PLoS One       Date:  2016-09-09       Impact factor: 3.240

8.  Therapeutic and Diagnostic Value of Caspase-12 and Study of Growth Differentiation Factor-15 in Patients with Acute Myocar-dial Infarction.

Authors:  Changqing Sun; Xiulin Li; Daoqing Wang; Liming Wang
Journal:  Iran J Public Health       Date:  2020-12       Impact factor: 1.429

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.